What we do

Using a simple blood test, ctDNA analysis is a new tool for oncologists to detect cancer, stratify patients, and monitor individual response to treatment.

A non-invasive liquid biopsy offers a revolution in how cancer is detected, monitored and treated, providing the potential for frequent tumor profiling and a more personalized approach to cancer care.

Inivata works with leading industry and academic researchers to develop new clinical applications for liquid biopsy and ctDNA analysis.

Our ambition is to provide genuine and practical benefits to the healthcare industry, from physicians and patients, to pharmaceutical companies and payers.

Our Mission

We are transforming the lives of cancer patients and their families
through the power of liquid biopsy.

Find out more about the clinical implications of liquid biopsy

Our Team

Our management team

Thomas Schlumpberger PhD
VP, Business Development
Read more

Dr Thomas Schlumpberger joined Inivata in August 2018 as VP, Business Development.

Previously, Thomas held a leadership position at Singulex in 2015 as their Head of Diagnostic Business & Vice President Diagnostics with 15+ years’ experience in the IVD, life science and pharmaceutical industries. In his role as VP of Corporate Development and Alliance Management, he was charged with capturing growth opportunities outside of clinical diagnostics. Additionally, he lead all collaborations and agreements necessary to grow and operate the Singulex CLIA laboratory and the Singulex diagnostic business. Notably, he sourced and co-negotiated $50 million minority investment from Grifols.  Thomas also previously held a key role within business development at Annai Systems and AliveCor. Here, he identified growth opportunities, managed deals and supported sales and product development efforts. Before then, he served as the Chief Commercial Officer at Invitae (f/k/a Locus Development), where he had responsibility for commercialization and product launches.

Earlier in his industry career, Thomas served with Epocal as Senior VP of International Sales and Business Development over 5 years. In this role, he successfully executed multiple deals, specifically $275M with Alere. He also built and operated international business, including distribution deals and product launches which drove additional revenues. Before joining the healthcare industry, Thomas served as a Consultant at McKinsey & Company. He currently sits on the board of DxEconomics and serves as Deal Advisor to CroMedX, both in Toronto, ON.

Clive Morris
Chief Executive Officer

Clive joined the leadership team in May 2016 and become CEO in July 2018.  Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ. He has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. Most recently Clive founded and lead Health Innovation Manchester, to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. He is also a non-executive director of Wheatsheaf investments and the InnovateUK Medicines Discovery Catapult. Clive is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, has an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester, and trained as a physician at the University of Manchester.

Jamie Platt PhD
Chief Operations Officer

Jamie leads the global clinical laboratory operations at Inivata. She was engaged as a consultant in March 2017 and joined the team on a full-time basis in Sept 2017. She has extensive expertise in sequencing and molecular systematics, including population genetics. During her 15 years in clinical diagnostics, Jamie has developed and validated numerous high complexity sequencing assays in the clinical areas of Oncology, Infectious Disease and Molecular Genetics and has introduced custom, industrial-grade automation to high complexity, sequencing assays. She has spent more than 10 years overseeing development and validation of Next Generation Sequencing Assays for both clinical diagnostics and clinical trials and has special interest in applying advanced sequencing technologies (NGS) to improve personalized healthcare. Jamie received her PhD in Molecular and Cellular Biology from Oregon State University and completed postdoctoral training in population genetics at the University of California, Berkeley.

Nitzan Rosenfeld PhD
Chief Scientific Officer

Nitzan is one of the founders of Inivata and Chief Scientific Officer. Nitzan is a world-leader in circulating tumor DNA biology and joined Cancer Research UK’s Cambridge Research Institute, now part of the University of Cambridge in 2009, where he combines new molecular and genomics approaches to develop new diagnostics. Previously he was head of Computational Biology at Rosetta Genomics and led development of molecular diagnostic tests. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  In 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD. He originally trained in Physics, and specialized in quantitative molecular biology, obtaining a PhD in Systems Biology from the Weizman Institute of Science, Israel.

Tim Shannon
Chief Financial Officer

Tim joined Inivata in 2016 and leads the finance team. Prior to joining Inivata he formulated and implemented financial controls and process improvements supporting business growth and expansion most recently at Baxano Surgical and Talecris Biotherapeutics. His background in technology, life sciences, and distribution environments is particularly relevant as Inivata moves forward towards commercialization. While at Talecris, Tim managed the Initial Public Offering (IPO) at a $3.28 billion valuation and has managed merger and acquisition transactions. Tim also has operational business experience across critical issues including budgeting, investor relations, systems implementation, and risk management. Tim has a Bachelor of Science in Business Administration from Appalachian State University and is a CPA, having spent the first 15 years of his career with PwC.

Patrice Love
Director of People and Organisation Development

Patrice has led HR activities since the early formation of the company in 2014. She has experience in early stage start-ups and pre-IPO companies, particularly in the life science and technology sectors, both in Europe and USA. Patrice’s career started in BT and in the latter years, with BT Brightstar, BT’s first corporate incubator as Head of Operations. She was also a Director at British manufacturer, Timberwolf and before joining Inivata, she owned her own consultancy business, supporting start-ups with a range of services including Operations, HR, Marketing and Finance. During her consultancy, she moved to New York for a year where she set up a US business for a UK technology company. Patrice is a Board Member of the Suffolk Chamber of Commerce, Suffolk Business Women, and an Ambassador for Suffolk Inward Investment and until recently, a Trust Governor at Suffolk One college.

Thomas Schlumpberger PhD
VP, Business Development

Dr Thomas Schlumpberger joined Inivata in August 2018 as VP, Business Development.

Previously, Thomas held a leadership position at Singulex in 2015 as their Head of Diagnostic Business & Vice President Diagnostics with 15+ years’ experience in the IVD, life science and pharmaceutical industries. In his role as VP of Corporate Development and Alliance Management, he was charged with capturing growth opportunities outside of clinical diagnostics. Additionally, he lead all collaborations and agreements necessary to grow and operate the Singulex CLIA laboratory and the Singulex diagnostic business. Notably, he sourced and co-negotiated $50 million minority investment from Grifols.  Thomas also previously held a key role within business development at Annai Systems and AliveCor. Here, he identified growth opportunities, managed deals and supported sales and product development efforts. Before then, he served as the Chief Commercial Officer at Invitae (f/k/a Locus Development), where he had responsibility for commercialization and product launches.

Earlier in his industry career, Thomas served with Epocal as Senior VP of International Sales and Business Development over 5 years. In this role, he successfully executed multiple deals, specifically $275M with Alere. He also built and operated international business, including distribution deals and product launches which drove additional revenues. Before joining the healthcare industry, Thomas served as a Consultant at McKinsey & Company. He currently sits on the board of DxEconomics and serves as Deal Advisor to CroMedX, both in Toronto, ON.

Stacy Chick
Chief Commercial Officer

Stacy Chick brings over 25 years of US healthcare commercial experience to Inivata. Joining the team as a consultant in early 2018, Stacy quickly leveraged her commercial sales, marketing, market access and operations experience to accelerate the launch planning for InVisionFirst™-Lung. Based on these contributions, Stacy was appointed Chief Commercial Officer effective September 1, 2018. Prior to joining Inivata, Stacy held executive-level sales, marketing and market access leadership roles in public and privately-held life science companies including Bristol-Myers Squibb, Sanofi, UCB, Mallinckrodt and Archimedes Pharma. Stacy is a member of the International Association for the Study of Lung Cancer (IASLC), WBL and the Leukemia and Lymphoma Society.

What it is like to work here

We recognize the value of working together as a team, towards a common goal. As a team, our people help to shape the vision, culture, and direction of our company.

We aim to provide the highest standards of training and development, so that people working here are given the opportunity to advance their careers, as we look forward together to advance clinical outcomes and patient care. We provide a rewarding working environment, to accomplish great things, and to help people.